MedTrace Logo

A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT

NCT07400536 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2026-05-13

No results posted yet for this study

Summary

This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.

Conditions

  • Locally Advanced Cervical Carcinoma

Interventions

RADIATION

standard EBRT+Brachytherapy

EBRT: 45-50.4Gy, Brachytherapy: 7Gy×4 or 6Gy ×5

DRUG

Concurrent chemotherapy

Cisplatin 40mg/m2, qw×5

DRUG

Immune induction therapy

Cadonilimab （Moderate dose）+ albumin paclitaxel 90mg/m2, qw×6+ cisplatin 25mg/m2, qw×6

RADIATION

Reduced dose radiotherapy

EBRT: 45-50.4Gy; Brachytherapy: 6Gy×4

DRUG

Dose reduction concurrent chemotherapy

cisplatin 25mg/m2, qw×5

DRUG

Immunomaintenance therapy

Cadonilimab （Moderate dose）×9 or half a year

Sponsors & Collaborators

  • Akesobio

    collaborator INDUSTRY

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Guiling Li, PHD · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-24
Primary Completion
2028-07-18
Completion
2032-07-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07400536 on ClinicalTrials.gov